Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06801236 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), sponsored by Acerand Therapeutics (Hong Kong) Limited.

Recruiting
Registry status
Phase 1
Development phase
67
Enrollment target
8
Study locations

NCT06801236 is a Phase 1 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer) that is actively recruiting participants, run by Acerand Therapeutics (Hong Kong) Limited. The registered enrollment target is 67 participants, below the 125-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (46% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06801236, a Phase 1 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), is actively recruiting participants, sponsored by Acerand Therapeutics (Hong Kong) Limited.

RECRUITING
Registry status
Phase 1
Development phase
67 participants
Enrollment target
8
Study locations

Study Summary

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).

Conditions Studied

Prostate Cancer (Adenocarcinoma) mCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

  • DRUG ACE-232 tablets

Study Locations (8)

California

  • University of California San Diego, Moores Cancer Center - La Jolla

Florida

  • Moffitt Cancer Center, Tampa - Tampa

Maryland

  • University of Maryland, Greenebaum Comprehensive Cancer Center - Baltimore

Massachusetts

  • Harvard Medical School-Massachusetts General Hospital - Boston

Minnesota

  • M Health Fairview Clinics and Surgery Center - Minneapolis

Nebraska

  • Xcancer (Urology Cancer Center) - Omaha

South Carolina

  • Carolina Urologic Research Center - Myrtle Beach

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2025-05-12
Est. Completion 2028-08-01
Phase Phase 1

Sponsor

Acerand Therapeutics (Hong Kong) Limited

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06801236

The ClinicalTrials.gov registry entry for NCT06801236 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (46% lower). The listed sponsor is Acerand Therapeutics (Hong Kong) Limited, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which ACE-232 tablets is the first listed.

NCT06801236 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT06801236 about?

NCT06801236 is a clinical study titled "Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer". This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).

What is the current status of trial NCT06801236?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2025-05-12. Estimated completion is 2028-08-01.

What conditions does trial NCT06801236 study?

This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer).

What interventions are being tested in trial NCT06801236?

The interventions under investigation include: ACE-232 tablets (DRUG).

Who is sponsoring clinical trial NCT06801236?

This trial is sponsored by Acerand Therapeutics (Hong Kong) Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06801236 being conducted?

This trial has 8 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer (Adenocarcinoma)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer (Adenocarcinoma)

All registered trials for this condition

mCRPC (Metastatic Castration-resistant Prostate Cancer)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.